42 results
To evaluate whether integral AF treatment in primary care is non-inferior in terms of reducing all-cause mortality (primary outcome) and specific cardiac mortality and hospitalization and non-cardiac hospitalization (secondary outcomes), as compared…
The study has two main objectives. The first objective is to estimate the extra yield in detected cases of AF in patients aged 65 years and over, using case finding. The second is to compare three methods to detect AF.
In this study, the main clinical hypothesis is that the TIMI clinically significant bleeding rates will not be different between the rivaroxaban and VKA treatment strategy groups at Month 12.
We hypothesize that verapamil reduces progression from paroxysmal to persistent AF, improves rate control, exercise tolerance and quality of life and reduces costs compared to metoprolol.
Optimise post PVI management using ambulant continuous patient-driven eHealth monitoring after catheter ablation in the treatment of atrial fibrillation.Primary Objective:1) Determine the effect of eHealth on clinical management, outcomes and…
Answering the following questions:1. Main question: Is remifentanil a usefull medication for PSA in the emergency department?2. What is the recovery time of the patient when using fentanyl / propofol / remifentanil (time between last gift PSA…
St. Jude Medical developed the Merlin.net* Patient Care Network (Merlin.net* PCN) to augment or replace routine scheduled in-clinic visits. This investigation is designed with the hypothesis that detection of events (system integrity and diagnostic…
Time to recurrence of sustained VT and/or appropriate ICD therapy; ATP or shock
1. To determine the level of cognitive, emotional and cardiorespiratory impairment, daily functioning, participation in society, quality of life and partner strain up to one year after the survival of a cardiac arrest.2. To determine prognostic…
The primary objective of this study is to demonstrate that the efficacy of rivaroxaban, a direct FXa inhibitor, is non-inferior to that of dose-adjusted warfarin for the prevention of thromboembolic events in subjects with non-valvular atrial…
This amendment (extension to CRT-D subjects) aims to assess the economic effects of HM technology vs. classical follow-up of CRT-D patients from two perspectives: 1) the cost-effectiveness for the payer of health care, and 2) the economic impact on…
The objective of this study is to determine the effectiveness of the CHA2DS2-VASc prediction model as directive for the preventive management of AF patients in the first line.
Primary study objective:The primary objective of this study is to evaluate the clinical outcome of dual-chamber ICD therapy with minimized ventricular pacing compared with single-chamber device therapy with settings which are common in clinical…
To determine whether a dosing algorithm containing genetic information increases the time within therapeutic INR range during anticoagulation therapy with phenprocoumon compared to a dosing regimen that does not contain this genetic information.…
Reduction of ICD/CRT-D follow-up by telemonitoring in a feasible way.
The main objective of this study is to compare the occurrence of next ICD shock therapy for VT or VF in patients with hospital presentation for an ICD shock therapy for VT or VF, with a history of a myocardial infarction, between patients randomized…
The purpose of this study is to do research what the effect of the BMI and fat percentage is on the speed of cooling.
PRIMARY OBJECTIVETo evaluate the time to first documented event of atrial fibrillation by 6 months continuous rhythm monitoring versus Standard of Care treatment in patients with a recent cryptogenic stroke or TIA without documented history of…
To determine whether a dosing algorithm containing genetic information increases the time within therapeutic INR range during anticoagulation therapy with acenocoumarol compared to a dosing regimen that does not contain this genetic information.…
The primary study objective is to compare the rate of major CIED infections through 12-months post-implant between the TYRX envelope group and the control group.